CEO: Jacques Essinger
Sector: Medtech, Cardiovascular
Location: Ecublens, Switzerland
Investment Stage: Growth
Investment Status: Acquired by Boston Scientific in 2017
Year Invested: 2016
Symetis specialises in the development, manufacturing and marketing of next-generation percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions.
Symetis was acquired by Boston Scientific in 2017.
See Symetis related news here